Radiolabeled and fluorescent PARP inhibitors for imaging and radiotherapy
US11161865B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 24, 2018 |
| Grant date | Nov 2, 2021 |
| Priority date | — |
| Expiry date | Jun 18, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/91142
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to compounds of Formula I and II, wherein R1-R20 and FL are defined herein. Also provided are methods of targeting alpha-radiation to poly(ADP-ribose)polymerase 1 (PARP-1) enzyme expression, reducing proliferation of cancer cells, reducing proliferation of cancer cells, detecting intact and enzymatically active poly(ADP-ribose)polymerase 1 (PARP-1) enzyme expression, detecting PARP-1 enzyme expression in a subjects tissue sample, monitoring cancer treatment in a subject, or detecting a PARP-1 receptive cancer in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.